Patents by Inventor Garth Kinberger
Garth Kinberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220025370Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.Type: ApplicationFiled: July 1, 2021Publication date: January 27, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
-
Publication number: 20210346509Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.Type: ApplicationFiled: April 15, 2021Publication date: November 11, 2021Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
-
Patent number: 11104899Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.Type: GrantFiled: June 18, 2018Date of Patent: August 31, 2021Assignee: lonis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
-
Publication number: 20200270609Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.Type: ApplicationFiled: March 9, 2020Publication date: August 27, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
-
Publication number: 20200268898Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.Type: ApplicationFiled: November 7, 2018Publication date: August 27, 2020Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
-
Patent number: 10751419Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: GrantFiled: September 7, 2018Date of Patent: August 25, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Publication number: 20190209694Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: ApplicationFiled: September 7, 2018Publication date: July 11, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Publication number: 20190136234Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.Type: ApplicationFiled: June 18, 2018Publication date: May 9, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
-
Publication number: 20190134214Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.Type: ApplicationFiled: May 4, 2017Publication date: May 9, 2019Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury III
-
Publication number: 20190127737Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.Type: ApplicationFiled: November 5, 2018Publication date: May 2, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
-
Patent number: 10098959Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: GrantFiled: May 1, 2015Date of Patent: October 16, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Satyen P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Patent number: 10023861Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.Type: GrantFiled: August 29, 2012Date of Patent: July 17, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
-
Patent number: 9738895Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.Type: GrantFiled: February 10, 2015Date of Patent: August 22, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
-
Patent number: 9598693Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activating in a cell.Type: GrantFiled: July 27, 2015Date of Patent: March 21, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
-
Publication number: 20170043025Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: ApplicationFiled: May 1, 2015Publication date: February 16, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Satyen P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Publication number: 20160122761Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.Type: ApplicationFiled: June 23, 2014Publication date: May 5, 2016Applicant: Isis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
-
Publication number: 20150322436Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activating in a cell.Type: ApplicationFiled: July 27, 2015Publication date: November 12, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
-
Publication number: 20150315579Abstract: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. The motifs are defined by positioning of differentially modified nucleosides wherein at least the sugar moieties are different. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: ApplicationFiled: February 6, 2015Publication date: November 5, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Eric G. Marcusson, Eric E. Swayze
-
Patent number: 9127272Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activing in a cell.Type: GrantFiled: January 18, 2012Date of Patent: September 8, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
-
Publication number: 20150167006Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.Type: ApplicationFiled: February 10, 2015Publication date: June 18, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Eric E. Swayze, Balrkishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger